What is Rna Diagnostics?
Rna Diagnostics is a clinical-stage molecular diagnostics company dedicated to enhancing cancer care. Its proprietary Veridapt DX predictive biomarker platform is designed to measure a tumor's response to cancer drugs, providing physicians with critical insights as early as five weeks into therapy. This enables more informed treatment decisions for oncologists, patients, and payers, aiming for improved patient outcomes and cost efficiencies. While initially focused on primary breast cancer, the platform's adaptability extends to any solid tumor and cancer drug therapy.
How much funding has Rna Diagnostics raised?
Rna Diagnostics has raised a total of $5M across 1 funding round:
Series A
$5M
Series A (2019): $5M with participation from iGAN Partners
Key Investors in Rna Diagnostics
iGAN Partners
iGAN Partners is an investor in Rna Diagnostics, participating in its Series A funding round. Further details on their investment focus are not specified.
What's next for Rna Diagnostics?
The company's recent major strategic investment, following its Series A financing, suggests a phase of accelerated scaling and market penetration. This capital infusion is likely to fuel further development of the Veridapt DX platform, expand its clinical applications across various solid tumors, and strengthen its commercialization efforts. Rna Diagnostics is positioned to become a key player in precision oncology, offering data-driven solutions that optimize cancer treatment strategies.
See full Rna Diagnostics company page
